Compare UNB & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UNB | MOLN |
|---|---|---|
| Founded | 1891 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.6M | 137.2M |
| IPO Year | 1999 | 2021 |
| Metric | UNB | MOLN |
|---|---|---|
| Price | $22.96 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | ★ 4.1K | 2.1K |
| Earning Date | 10-21-2026 | 10-29-2026 |
| Dividend Yield | ★ 6.38% | N/A |
| EPS Growth | ★ 25.52 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.65 | $3.40 |
| 52 Week High | $26.41 | $5.36 |
| Indicator | UNB | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 39.28 |
| Support Level | N/A | N/A |
| Resistance Level | $24.16 | $4.19 |
| Average True Range (ATR) | 0.40 | 0.11 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 10.26 | 19.54 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The Company has one definable business segment, Union Bank, which provides full retail, commercial, municipal banking, and wealth management and trust services throughout its 18 branch banking locations, three loan centers, and several ATMs covering northern Vermont and northern New Hampshire. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.